Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.6652W HIGH $53.19
Volume
6.35 M
Value Traded
336.12 M
Short % Float
4.92%
Days to Cover
1.5
+0.11%Week
+0.36%1 Month
+43.11%3 Month
+208.66%6 Month
+164.75%5 Year
+212.39%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.12 B
EPS (TTM)
-1.03
P/E Ratio
-
Ent. Value
5.10 B
Total Shares
115.57 M
Float Shares
112.45 M
Insiders
8.73%
Institutions
100.41%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TERN Catalyst Timeline
Dated clinical, regulatory and corporate events for Terns Pharmaceuticals, Inc.
Past FDA Catalysts and PDUFA Decisions
How TERN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-12 | TERN-701 (next-generation allosteric BCR-ABL inhibitor) | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
4
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TERN-701 Small moleculeNCT06163430 | Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | RECRUITING | 180 | May 1, 2030 | ||||||
| TERN-601 Small moleculeCompletedNCT06854952 | Overweight or Obesity | Phase 2 | COMPLETED | 167 | Sep 1, 2025 | ||||||
| TERN-501 Small moleculeCompletedNCT05415722 | NASH - Nonalcoholic Steatohepatitis | Phase 2 | COMPLETED | 162 | Jul 1, 2023 | ||||||
| TERN-201 Small moleculeCompletedNCT04897594 | NASH - Nonalcoholic Steatohepatitis | Phase 1 | COMPLETED | 52 | Sep 1, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every TERN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TERN-701 BreakthroughOrphan | chronic myeloid leukemia (CML) | Phase 1/2 | 2026-01-07 | safety profile: 87% (55/63) of patients remained on treatment as of the data cutoff; no dose limiting toxicities: No dose-limiting toxicities were observed in dose escalation; grade 3 or higher teaes: Grade 3 or higher TEAEs were all less than 10%, most commonly neutropenia (8%) and thrombocytopenia (8%); mmr achievement rate: 75% (18/24) in evaluable patients enrolled at the recommended phase 2 dose range of >320mg QDRead More | Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare ConferenceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Azelby RobertDirector | Disposition | -90,000 | $0.00 | 05/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TERN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 3 % (76.5 %) | 300.24 M | 5.70 M | 30.92% ( 1.34 M) |
TERN Institutional Ownership Trends
TERN Short Interest
Shares sold short, counted twice a month.
4.92%
Short % of Float
of tradable shares sold short
5.5M
Shares Sold Short
-31.3% vs prior count
1.5 Low
Days to Cover
trading days of normal volume to buy every short share back
3.8M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TERN ranks across every disease it competes in
Competitive Position is a premium feature
See how TERN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTERN News
About Terns Pharmaceuticals, Inc.
Headquarters1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY, CA, 94404
BIOPHARMAWATCH ELITE PLUS
Trade the next TERN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime